Pancreatic Cancer Research

ResearcherChulalongkorn UniversityActive in the last 2 years

Hiroyuki Isayama

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3308-9326; OpenAlex author ID A5073049896, A5137939351. Sources: OpenAlex.

Their work

Papers
71 (first author 19, last author 8)
Trials
0
Grants
0
Labs led
1
Collaborators
147
Papers, trials and grants by year

2011: 4 papers · 2012: 6 papers · 2013: 10 papers · 2014: 10 papers · 2015: 5 papers · 2016: 4 papers · 2017: 6 papers · 2018: 2 papers · 2019: 6 papers · 2020: 4 papers · 2021: 5 papers · 2022: 2 papers · 2023: 2 papers · 2024: 1 paper · 2025: 3 papers · 2026: 1 paper

Papers 50 of 71

  1. Evaluation of tumor detection capability for pancreatic ductal adenocarcinoma concomitant with intraductal papillary mucinous neoplasm in each MRI sequence. Last author DOI 10.4103/sjg.sjg_91_26↗
  2. Gadoxetic acid-enhanced magnetic resonance imaging predicts early nab-paclitaxel-induced peripheral neuropathy during pancreatic cancer treatment: A pilot stud… Last author DOI 10.1016/j.jphs.2025.03.009↗
  3. Impact of Statin Use on Survival in Patients With Unresectable Pancreatic cancer Receiving Gemcitabine Plus Nab-Paclitaxel: A Multicenter Retrospective Study. Co-author DOI 10.1097/mpa.0000000000002411↗
  4. Differentiation of Autoimmune Pancreatitis From Pancreatic Ductal Adenocarcinoma by Diffusion-Weighted Magnetic Resonance Imaging With Weighted Diffusion Subtr… Co-author DOI 10.7759/cureus.81438↗
  5. Survival Analysis of Conversion Surgery in Borderline Resectable and Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma Addressing Selection and Im… Co-author DOI 10.1245/s10434-024-16203-x↗
  6. Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis. Co-author DOI 10.1007/s10147-023-02317-x↗
  7. STNM01, the RNA oligonucleotide targeting carbohydrate sulfotransferase 15, as second-line therapy for chemotherapy-refractory patients with unresectable pancr… Co-author DOI 10.1016/j.eclinm.2022.101731↗
  8. Synopsis of a clinical practice guideline for pancreatic ductal adenocarcinoma with peritoneal dissemination in Japan; Japan Peritoneal Malignancy Study Group. Co-author DOI 10.1002/jhbp.1085↗
  9. Pancreatic Adenocarcinoma With Strong Expression of Interleukin-13 Receptor α2 Shows a Poor Response to Gemcitabine-Based Chemotherapy. Last author DOI 10.1097/mpa.0000000000002151↗
  10. A phase I study of intraperitoneal paclitaxel combined with gemcitabine plus nab-paclitaxel for pancreatic cancer with peritoneal metastasis. Co-author DOI 10.1007/s10637-020-00982-7↗
  11. Effect of Mirogabalin on Chemotherapy-induced Peripheral Neuropathy Caused by Gemcitabine Plus Nab-paclitaxel Therapy in Pancreatic Cancer Patients: A Pilot St… Last author DOI 10.21203/rs.3.rs-948459/v2↗
  12. Duration of Reduced CA19-9 Levels Is a Better Prognostic Factor Than Its Rate of Reduction for Unresectable Locally Advanced Pancreatic Cancer. Last author DOI 10.3390/cancers13164224↗
  13. IL-13Rα2 Is a Biomarker of Diagnosis and Therapeutic Response in Human Pancreatic Cancer. Last author DOI 10.3390/diagnostics11071140↗
  14. A Prospective Multicenter Study of Partially Covered Metal Stents in Patients Receiving Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancr… Co-author DOI 10.5009/gnl19302↗
  15. Soluble VCAM-1 promotes gemcitabine resistance via macrophage infiltration and predicts therapeutic response in pancreatic cancer. Co-author DOI 10.1038/s41598-020-78320-3↗
  16. Successful Management of Hemosuccus Pancreaticus due to Pancreatic Adenocarcinoma by Chemoradiotherapy. Last author DOI 10.2169/internalmedicine.4372-19↗
  17. A Novel Role of Interleukin 13 Receptor alpha2 in Perineural Invasion and its Association with Poor Prognosis of Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers12051294↗
  18. Screening Strategy of Pancreatic Cancer in Patients with Diabetes Mellitus. Co-author DOI 10.3390/diagnostics10080572↗
  19. A phase II trial of gemcitabine, S-1 and LV combination (GSL) therapy in patients with advanced pancreatic cancer. First author DOI 10.1007/s10637-018-0691-9↗
  20. Covered and uncovered biliary metal stents provide similar relief of biliary obstruction during neoadjuvant therapy in pancreatic cancer: a randomized trial. Co-author DOI 10.1016/j.gie.2019.06.032↗
  21. Diagnostic yield of the plasma free amino acid index for pancreatic cancer in patients with diabetes mellitus. First author DOI 10.1016/j.pan.2019.07.002↗
  22. Blocking CXCLs-CXCR2 axis in tumor-stromal interactions contributes to survival in a mouse model of pancreatic ductal adenocarcinoma through reduced cell invas… Co-author DOI 10.1038/s41389-018-0117-8↗
  23. Brain metastasis in pancreatic cancer: Two case reports. Co-author DOI 10.1097/md.0000000000014227↗
  24. Development of pancreatic cancer during observation for hepatocellular carcinoma: A retrospective cohort study. Co-author DOI 10.4103/sjg.sjg_56_19↗
  25. A phase II trial of gemcitabine, S-1 and LV combination (GSL) neoadjuvant chemotherapy for patients with borderline resectable and locally advanced pancreatic … First author DOI 10.1007/s12032-018-1158-8↗
  26. A Multicenter Open-Label Randomized Controlled Trial of Pancreatic Enzyme Replacement Therapy in Unresectable Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001079↗
  27. Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patien… Co-author DOI 10.1007/s00280-017-3250-8↗
  28. Development of pancreatic cancer is predictable well in advance using contrast-enhanced CT: a case-cohort study. Co-author DOI 10.1007/s00330-017-4895-8↗
  29. Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data. Co-author DOI 10.1038/bjc.2017.128↗
  30. The Role of Pancreatic Enzyme Replacement Therapy in Unresectable Pancreatic Cancer: A Prospective Cohort Study. Co-author DOI 10.1097/mpa.0000000000000767↗
  31. Thromboembolisms in Advanced Pancreatic Cancer: A Retrospective Analysis of 475 Patients. Co-author DOI 10.1097/mpa.0000000000000889↗
  32. Multicenter Phase II Study of Intravenous and Intraperitoneal Paclitaxel With S-1 for Pancreatic Ductal Adenocarcinoma Patients With Peritoneal Metastasis. Co-author DOI 10.1097/sla.0000000000001705↗
  33. Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites. First author DOI 10.1007/s10637-016-0369-0↗
  34. Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer. Co-author DOI 10.1016/j.ejca.2016.05.016↗
  35. A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer. Co-author DOI 10.1093/annonc/mdv603↗
  36. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer. Co-author DOI 10.18632/oncotarget.11129↗
  37. The inhibition of renin-angiotensin system in advanced pancreatic cancer: an exploratory analysis in 349 patients. First author DOI 10.1007/s00432-014-1873-2↗
  38. Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer. Co-author DOI 10.1038/bjc.2015.103↗
  39. Pancreatic cancer with malignant ascites: clinical features and outcomes. First author DOI 10.1097/mpa.0000000000000290↗
  40. Response to Y. Sasaki et al.: Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer? Co-author DOI 10.1111/cas.12709↗
  41. [IPMN and pancreatic cyst as high risk of pancreatic cancer]. Co-author DOI 10.11405/nisshoshi.112.1474↗
  42. Improved survival with combined gemcitabine and S-1 for locally advanced pancreatic cancer: pooled analysis of three randomized studies. Last author DOI 10.1002/jhbp.130↗
  43. A phase I trial of gemcitabine, S-1 and LV combination (GSL) therapy in advanced pancreatic cancer. First author DOI 10.1007/s00280-014-2563-0↗
  44. Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis. First author DOI 10.1007/s12029-014-9603-1↗
  45. Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy. Co-author DOI 10.1038/bjc.2014.131↗
  46. Loss of histone demethylase KDM6B enhances aggressiveness of pancreatic cancer through downregulation of C/EBPα. Co-author DOI 10.1093/carcin/bgu136↗
  47. EBM-based Clinical Guidelines for Pancreatic Cancer (2013) issued by the Japan Pancreas Society: a synopsis. Co-author DOI 10.1093/jjco/hyu127↗
  48. A R0 resection case of initially unresectable metastatic pancreatic cancer downstaged by FOLFIRINOX therapy. First author DOI 10.1097/mpa.0000000000000139↗
  49. Smoking, family history of cancer, and diabetes mellitus are associated with the age of onset of pancreatic cancer in Japanese patients. Co-author DOI 10.1097/mpa.0000000000000158↗
  50. Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer. Co-author DOI 10.1111/cas.12501↗

Closest collaborators

The 25 strongest of 147 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yousuke Nakai · 49 shared papers, 2011–2025 · strength 2.58
  2. Kazuhiko Koike · 46 shared papers, 2011–2021 · strength 2.15
  3. Suguru Mizuno · 30 shared papers, 2011–2021 · strength 1.37
  4. Hirofumi Kogure · 33 shared papers, 2011–2021 · strength 1.36
  5. Naminatsu Takahara · 26 shared papers, 2011–2022 · strength 1.29
  6. Minoru Tada · 33 shared papers, 2011–2019 · strength 1.21
  7. Kei Saito · 15 shared papers, 2014–2025 · strength 1.18
  8. Toshio Fujisawa · 8 shared papers, 2020–2026 · strength 1.06
  9. Yusuke Takasaki · 6 shared papers, 2021–2026 · strength 1.02
  10. Hideaki Ijichi · 24 shared papers, 2012–2020 · strength 0.98
  11. Tsuyoshi Hamada · 21 shared papers, 2011–2021 · strength 0.95
  12. Ko Tomishima · 6 shared papers, 2020–2026 · strength 0.91
  13. Saburo Matsubara · 16 shared papers, 2011–2025 · strength 0.80
  14. Dai Mohri · 17 shared papers, 2011–2025 · strength 0.77
  15. Koji Miyabayashi · 20 shared papers, 2012–2020 · strength 0.73
  16. Kazunaga Ishigaki · 9 shared papers, 2015–2021 · strength 0.60
  17. Naoki Sasahira · 19 shared papers, 2011–2019 · strength 0.60
  18. Takashi Sasaki · 19 shared papers, 2011–2015 · strength 0.57
  19. Takashi Sasaki · 8 shared papers, 2011–2025 · strength 0.53
  20. Tomotaka Saito · 8 shared papers, 2014–2021 · strength 0.53
  21. Keisuke Yamamoto · 14 shared papers, 2011–2020 · strength 0.49
  22. Akio Saiura · 2 shared papers, 2024–2025 · strength 0.45
  23. Tsuyoshi Takeda · 5 shared papers, 2015–2025 · strength 0.44
  24. Kazumichi Kawakubo · 12 shared papers, 2011–2021 · strength 0.43
  25. Takuji Okusaka · 7 shared papers, 2014–2017 · strength 0.31

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.